Evidence map›Paper›PMID 29890894›Full record

ArticleTechnology in cancer research & treatment2018

Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer.

Luke Stanisce, Yekaterina Koshkareva, Qianyi Xu, Ashish Patel, Christian Squillante, Nadir Ahmad, Kumar Rajagopalan, Gregory J Kubicek

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Luke Stanisce1 Cooper Medical School of Rowan University, Camden, NJ, USA.
Yekaterina Koshkareva2 Department of Otolaryngology-Head and Neck Surgery, MD Anderson Cancer Center at Cooper University, Camden, NJ, USA.
Qianyi Xu3 Department of Radiation Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ, USA.
Ashish Patel3 Department of Radiation Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ, USA.
Christian Squillante4 Department of Medical Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ, USA.
Nadir Ahmad2 Department of Otolaryngology-Head and Neck Surgery, MD Anderson Cancer Center at Cooper University, Camden, NJ, USA.
Kumar Rajagopalan4 Department of Medical Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ, USA.
Gregory J Kubicek3 Department of Radiation Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ, USA.ORCID 0000-0001-9700-1760
Cooper University Hospital · USCooper Medical School of Rowan University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLocally recurrent, previously irradiated primary head and neck tumors have historically been associated with poor outcomes. Stereotactic body radiation therapy has emerged as a feasible and promising treatment option for tumor recurrence, particularly in nonsurgical candidates. This study aimed to assess the associated outcomes of stereotactic body radiation therapy used in this setting.

methodsRetrospective analysis of a prospectively collected database of 25 patients treated with CyberKnife for unresectable, recurrent head and neck cancer in a previously irradiated field. The primary end points evaluated were rates of survival, tumor control, and treatment-related toxicities.

resultsMedian survival of the study population was 7.5 months (range, 1.5-47.0 months). Median survival of the 20 (80%) patients who were treated with curative purpose was 8.3 months. One-year overall survival rate for the entire population was 32%. The respective 1-year and 2-year survival rates for the curative subcohort were 40% and 20%, respectively. Local and locoregional failure occurred in 8 (32%) and 7 (28%) patients, respectively. Low severe acute (4%) and late (6%) treatment-related toxicity rates were observed. No grade 4 or 5 toxicities were observed.

conclusionStereotactic body radiation therapy is a viable treatment option for patients with unresectable, recurrent head and neck cancer. Significant tumor control rates are achievable with minimal severe toxicity. Although perhaps associated with patient selection and a heterogeneous sample, overall survival of stereotactic body radiation therapy outcomes appears unfavorable.

Indexed as

AdultAgedAged, 80 and overFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalRadiosurgeryRetrospective StudiesSalvage TherapyTreatment OutcomeCyberKnifehead and neck cancerrecurrencestereotactic body radiation therapy

Identifiers

PMID29890894
PMCPMC6024262
OpenAlexW2808647087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.